Bronchoscopy in Determining the Effect of E-Cigarette Smoking on Biomarkers in the Lungs

NCT03691350 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2026-04-23

Study results available
· View outcomes & findings →

Summary

This trial studies biomarkers obtained by bronchoscopy (bronchoalveolar lavage and lung brushings) to determine the effect of smoking e-cigarettes on the lungs. Studying samples of lung cells from participants who smoke e-cigarettes may help doctors learn more about changes that occur in deoxyribonucleic acid and identify biomarkers related to cancer.

Conditions

  • Cigarette Smoker
  • Current Every Day Smoker

Interventions

PROCEDURE

Bronchoscopy with Bronchoalveolar Lavage

Undergo bronchoscopy with bronchoalveolar lavage

DRUG

Cigarette

Smoke usual brand

OTHER

Electronic Cigarette

Smoke SREC with nicotine

OTHER

Electronic Cigarette

Smoke SREC without nictoine

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Nicotine Replacement

Receive NRT comprising patch, gum, or lozenge

OTHER

Questionnaire Administration

Ancillary studies

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH
  • Ohio State University Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Peter Shields, MD · Ohio State University Comprehensive Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
52 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-09-17
Primary Completion
2023-10-23
Completion
2024-03-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03691350 on ClinicalTrials.gov